These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1460 related articles for article (PubMed ID: 33558296)

  • 1. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.
    Martinez MA
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
    White KM; Rosales R; Yildiz S; Kehrer T; Miorin L; Moreno E; Jangra S; Uccellini MB; Rathnasinghe R; Coughlan L; Martinez-Romero C; Batra J; Rojc A; Bouhaddou M; Fabius JM; Obernier K; Dejosez M; Guillén MJ; Losada A; Avilés P; Schotsaert M; Zwaka T; Vignuzzi M; Shokat KM; Krogan NJ; García-Sastre A
    Science; 2021 Feb; 371(6532):926-931. PubMed ID: 33495306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.
    Varona JF; Landete P; Lopez-Martin JA; Estrada V; Paredes R; Guisado-Vasco P; Fernandez de Orueta L; Torralba M; Fortun J; Vates R; Barberan J; Clotet B; Ancochea J; Carnevali D; Cabello N; Porras L; Gijon P; Monereo A; Abad D; Zuñiga S; Sola I; Rodon J; Vergara-Alert J; Izquierdo-Useros N; Fudio S; Pontes MJ; de Rivas B; Giron de Velasco P; Nieto A; Gomez J; Aviles P; Lubomirov R; Belgrano A; Sopesen B; White KM; Rosales R; Yildiz S; Reuschl AK; Thorne LG; Jolly C; Towers GJ; Zuliani-Alvarez L; Bouhaddou M; Obernier K; McGovern BL; Rodriguez ML; Enjuanes L; Fernandez-Sousa JM; Krogan NJ; Jimeno JM; Garcia-Sastre A
    Life Sci Alliance; 2022 Apr; 5(4):. PubMed ID: 35012962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment.
    Aguareles J; Villares Fernández P; Forné C; Martí-Ballesteros EM; Pradillo Fernández V; Sotres-Fernandez G; de la Fuente-Burguera A; Navarro-San Francisco C; Buzón-Martín LM; García-Delangue T; Aiello FT; Carnevali-Ruiz D; Lloris R; Luepke-Estefan XE; López-Martín JA; Jimeno JM; García-Casas A; Guisado-Vasco P
    Infect Dis (Lond); 2024 Jul; 56(7):575-580. PubMed ID: 38743059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations.
    Vishvakarma VK; Singh MB; Jain P; Kumari K; Singh P
    Amino Acids; 2022 Feb; 54(2):205-213. PubMed ID: 34807314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.
    Sachse M; Tenorio R; Fernández de Castro I; Muñoz-Basagoiti J; Perez-Zsolt D; Raïch-Regué D; Rodon J; Losada A; Avilés P; Cuevas C; Paredes R; Segalés J; Clotet B; Vergara-Alert J; Izquierdo-Useros N; Risco C
    Antiviral Res; 2022 Apr; 200():105270. PubMed ID: 35231500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational Prediction of the Potential Target of SARS-CoV-2 Inhibitor Plitidepsin via Molecular Docking, Dynamic Simulations and MM-PBSA Calculations.
    El Hassab MA; Hemeda LR; Elsayed ZM; Al-Rashood ST; Abdel-Hamid Amin MK; Abdel-Aziz HA; Eldehna WM
    Chem Biodivers; 2022 Feb; 19(2):e202100719. PubMed ID: 34813168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.
    Guisado-Vasco P; Carralón-González MM; Aguareles-Gorines J; Martí-Ballesteros EM; Sánchez-Manzano MD; Carnevali-Ruiz D; García-Coca M; Barrena-Puertas R; de Viedma RG; Luque-Pinilla JM; Sotres-Fernandez G; Fernández-Sousa JM; Luepke-Estefan XE; López-Martín JA; Jimeno JM
    J Hematol Oncol; 2022 Jan; 15(1):4. PubMed ID: 35012608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19.
    Papapanou M; Papoutsi E; Giannakas T; Katsaounou P
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].
    Reina J
    Rev Esp Quimioter; 2021 Oct; 34(5):402-407. PubMed ID: 33902254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.
    Kröker A; Tirzīte M
    Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.
    Paul SS; Biswas G
    Mini Rev Med Chem; 2021; 21(9):1123-1143. PubMed ID: 33355053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update of anti-viral treatment of COVID-19.
    Şimşek-Yavuz S; Komsuoğlu Çelikyurt FI
    Turk J Med Sci; 2021 Dec; 51(SI-1):3372-3390. PubMed ID: 34391321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Hopes for Drugs against COVID-19 Come from the Sea.
    Taglialatela-Scafati O
    Mar Drugs; 2021 Feb; 19(2):. PubMed ID: 33670191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy.
    Guisado-Vasco P; González-Cortijo L; D'Errico G; Serrera-Alvarez A; Sotres-Fernandez G; García-Coca M; Fernández-Sousa JM; Luepke-Estefan XE; López-Martín JA; Jimeno JM
    Ann Oncol; 2021 Oct; 32(10):1295-1297. PubMed ID: 34242743
    [No Abstract]   [Full Text] [Related]  

  • 19. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
    Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.